Fig. 1From: The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and designStudy design. Endpoint assessment periods. Admission for overnight plasma glucose monitoring and/or 6 days of ambulatory 24 h continuous glucose monitoringBack to article page